FDA
-
-
-
-
-
-
-
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
-
-
-
-
-
-
-
Voyager Therapeutics (VYGR) Presents Robust Preclinical Data from Tau Targeting Gene Therapy
-
-
-
-
-
-
-
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
-
-
-
-
-
-
-
Voyager Therapeutics (VYGR) Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
-
-
-
-
-
-
-
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
-
-
-
-
-
-
-
Voyager (VYGR) announces FDA has notified Neurocrine (NBIX) that it has placed clinical hold on RESTORE-1 clinical trial of NBIb-1817
-
-
-
-
-
-
-
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor F
-
326,550 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

